Breast Cancer Research and Treatment

, Volume 136, Issue 2, pp 559–564 | Cite as

Breast cancer incidence by estrogen receptor status in Denmark from 1996 to 2007

  • J. Bigaard
  • C. Stahlberg
  • M.-B. Jensen
  • M. Ewertz
  • N. Kroman


During the past 50 years, breast cancer incidence has increased by 2–3 % annually. Despite many years of testing for estrogen receptors (ER), evidence is scarce on breast cancer incidence by ER status. The aim of this paper was to investigate the increase in breast cancer incidence by ER status. Data were obtained from the clinical database of the Danish Breast Cancer Cooperative Group which holds nationwide data on diagnosis, including pathology, treatment, and follow-up on primary breast cancers since 1977. All Danish women <80 years diagnosed with primary breast cancer 1996–2007 were identified in this prospective register based study. ER status was evaluated using immunohistochemical staining by standardized laboratory methods in the Danish Pathology Departments and reported to the database. From 1996 to 2007, breast cancer incidence increased overall with a tendency to level off after 2002. In all women a significant decrease was found in ER unknown tumors. However, in both pre- and postmenopausal women, significant increases were seen in incidence of ER+ tumors; though the increase levelled off for premenopausal women after 2002. In postmenopausal women, the incidence of ER− breast cancer decreased significantly throughout the period. In women <35 years, we found a minor non-significant increase in both ER+ and ER− tumors. ER unknown decreased in all women and was the most distinct in premenopausal women aged 35+. We found a significant increase in ER+ breast cancer incidence in postmenopausal women whereas the incidence in premenopausal women (aged 35+) levelled off after 2002.


Breast cancer incidence Estrogen receptor status Epidemiology 



Estrogen receptor


Danish Breast Cancer Group


Immunohistochemical staining


Hormone replacement therapy


Annual percentage rate change


Conflict of interest

These authors declare that they have no conflict of interest.

Ethical standards

This study was performed in agreement with the Ethical Committees on Human Studies.


  1. 1.
    Lidegaard O, Kroman N (2005) The epidemiology of breast cancer. Eur Clin Obstet Gynaecol 1:24–28CrossRefGoogle Scholar
  2. 2.
    Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM (1994) Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74(5):1601–1606PubMedCrossRefGoogle Scholar
  3. 3.
    Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21(1):28–34PubMedCrossRefGoogle Scholar
  4. 4.
    Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99(15):1152–1161PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397–1402PubMedCrossRefGoogle Scholar
  6. 6.
    Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674PubMedCrossRefGoogle Scholar
  7. 7.
    Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28PubMedCrossRefGoogle Scholar
  8. 8.
    Cronin KA, Ravdin PM, Edwards BK (2009) Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 117(1):223–224PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM (2007) Shifting breast cancer trends in the United States. J Clin Oncol 25(25):3923–3929PubMedCrossRefGoogle Scholar
  10. 10.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059CrossRefGoogle Scholar
  11. 11.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford AA, Howard BV, Johnson KC, Katchen JM (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRefGoogle Scholar
  12. 12.
    Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587PubMedCrossRefGoogle Scholar
  13. 13.
    Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684–1692PubMedCrossRefGoogle Scholar
  14. 14.
    Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427PubMedCrossRefGoogle Scholar
  15. 15.
    von Euler-Chelpin M (2011) Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. Cancer Causes Control 22(2):181–187CrossRefGoogle Scholar
  16. 16.
    De P, Neutel CI, Olivotto I, Morrison H (2010) Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 102(19):1489–1495PubMedCrossRefGoogle Scholar
  17. 17.
    Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson I, Ahlgren J, Bergkvist L (2010) Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121(3):679–683PubMedCrossRefGoogle Scholar
  18. 18.
    Renard F, Vankrunkelsven P, Van EL, Henau K, Boniol M, Autier P (2010) Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 21(12):2356–2360PubMedCrossRefGoogle Scholar
  19. 19.
    Ewertz M, Duffy SW (1994) Incidence of female breast cancer in relation to prevalence of risk factors in Denmark. Int J Cancer 56(6):783–787PubMedCrossRefGoogle Scholar
  20. 20.
    Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMedGoogle Scholar
  21. 21.
    Fuglede N, Langballe O, Svendsen AL, Tjonneland A, Dalton SO, Johansen C (2006) Development in incidence of breast cancer in non-screened Danish women, 1973–2002—a population-based study. Int J Cancer 118(9):2366–2369PubMedCrossRefGoogle Scholar
  22. 22.
    Lokkegaard E, Lidegaard O, Moller LN, Agger C, Andreasen AH, Jorgensen T (2007) Hormone replacement therapy in Denmark, 1995–2004. Acta Obstet Gynecol Scand 86(11):1342–1351PubMedCrossRefGoogle Scholar
  23. 23.
    Talman ML, Rasmussen BB, Andersen J, Christensen IJ (2008) Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol 47(4):789–794PubMedCrossRefGoogle Scholar
  24. 24.
    Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT (2008) The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 47(4):506–524PubMedCrossRefGoogle Scholar
  25. 25.
    Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351PubMedCrossRefGoogle Scholar
  26. 26.
    MacMahon B (2006) Epidemiology and the causes of breast cancer. Int J Cancer 118(10):2373–2378PubMedCrossRefGoogle Scholar
  27. 27.
    Reeves GK, Pirie K, Green J, Bull D, Beral V (2009) Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer 100(3):538–544PubMedCrossRefGoogle Scholar
  28. 28.
    Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F et al (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111(5):762–771PubMedCrossRefGoogle Scholar
  29. 29.
    Schutze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjonneland A-M, Dahm CC, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC et al (2011) Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 342:d1584PubMedCrossRefGoogle Scholar
  30. 30.
    Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Goudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263PubMedCrossRefGoogle Scholar
  31. 31.
    Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8(4):R43PubMedCrossRefGoogle Scholar
  32. 32.
    Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430PubMedCrossRefGoogle Scholar
  33. 33.
    DeSantis C, Howlader N, Cronin KA, Jemal A (2011) Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20(5):733–739PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • J. Bigaard
    • 1
    • 7
  • C. Stahlberg
    • 2
  • M.-B. Jensen
    • 3
  • M. Ewertz
    • 4
    • 5
  • N. Kroman
    • 6
  1. 1.Department of Breast SurgeryRingsted HospitalRingstedDenmark
  2. 2.Department of PathologyOdense University HospitalOdenseDenmark
  3. 3.Danish Breast Cancer Cooperative Group (DBCG)RigshospitaletCopenhagenDenmark
  4. 4.Department of OncologyOdense University HospitalOdenseDenmark
  5. 5.Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
  6. 6.Department of Breast SurgeryRigshospitaletCopenhagenDenmark
  7. 7.HolteDenmark

Personalised recommendations